Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(1):70; doi:10.1093/jnci/dji016
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tanvetyanon, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanvetyanon, T.
Related Collections
Right arrowResponse to this Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

CORRESPONDENCE

Re: Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Metastatic Hormone-Refractory Prostate Cancer

Tawee Tanvetyanon

Correspondence to: Tawee Tanvetyanon, MD, Loyola University Stritch School of Medicine, Cardinal Bernardin Cancer Institute, 2160 S. First Ave., Maywood, IL 60153 (e-mail: ttanve@lumc.edu)

The first 10% of the full text of this article appears below.

Serious concerns arose as I read the article by Saad et al. (1). First, the authors concluded that long-term treatment with zoledronic acid was safe. However, in my opinion, a 24-month follow-up for this potent bisphosphonate is not sufficiently long to make that conclusion. Longer use (i.e., >40 months) of another nitrogen-containing bisphosphonate, pamidronate, has been . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Response to this Correspondence

RESPONSE: Re: Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Metastatic Hormone-Refractory Prostate Cancer
Fred Saad
J Natl Cancer Inst 2005 97: 70-71. [Extract] [Full Text] [PDF]